hailir(SH:603639)2025-01-22 11:50Financial Performance - The company expects a net profit of approximately 200 million yuan for 2024, a decrease of about 57.73% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be around 190 million yuan, reflecting a decline of approximately 61.43% year-on-year[3]. - In 2023, the net profit attributable to shareholders was 473.20 million yuan, with a profit total of 572.06 million yuan[5]. Market Factors - The decline in profit is primarily due to macroeconomic factors and market changes, leading to a decrease in market prices for some products[7]. Project Development - The company is advancing its Hengning Phase II project, with trial production of two intermediates and one active ingredient scheduled for late 2024[7]. - Hengning Biotech is the only domestic pesticide manufacturer holding registration certificates for the active ingredient Zolpidem and pesticide production licenses[7]. Strategic Plans - The company plans to enhance domestic marketing efforts, accelerate international market expansion, and increase technological innovation to improve profitability[7]. - The company aims to reduce costs and increase efficiency to enhance market competitiveness and market share[7]. Financial Reporting - The financial data provided is preliminary and subject to final confirmation in the official 2024 annual report[9]. - There are no significant uncertainties affecting the accuracy of this earnings forecast[8].